CG Oncology, Inc. Common stock (CGON) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Irvine, DE, United States. The current CEO is Arthur Kuan.
CGON has IPO date of 2024-01-25, 113 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $5.68B.
CG Oncology Inc is a clinical biopharmaceutical company developing innovative therapies for bladder cancer treatment. The company's lead product candidate, cretostimogene, is designed as a bladder-sparing therapeutic in clinical development for high-risk non-muscle invasive bladder cancer patients who have failed to respond to BCG immunotherapy, the current standard treatment. CG Oncology aims to address a significant unmet medical need in oncology by offering an alternative treatment option for BCG-unresponsive patients and positioning cretostimogene as a potential backbone therapy for bladder cancer management.
